Clinical Trial

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT07038096
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Small Cell Lung Cancer, Neuroendocrine Carcinoma
Enrollment 350 participants
Start Date 2025-09-23
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-05